A5036409076- Liver Diseases and Immunity
- Pediatric Hepatobiliary Diseases and Treatments
- Liver Disease Diagnosis and Treatment
- Diabetes and associated disorders
- Drug Transport and Resistance Mechanisms
- Gallbladder and Bile Duct Disorders
- Hepatitis Viruses Studies and Epidemiology
Cincinnati Children's Hospital Medical Center
2022-2024
Immune-mediated bile duct epithelial injury and toxicity of retained hydrophobic acids drive disease progression in fibrosing cholangiopathies such as biliary atresia or primary sclerosing cholangitis. Emerging therapies include pharmacological agonists to farnesoid X receptor (FXR), the master regulator hepatic synthesis, excretion, intestinal reuptake acids. Unraveling mechanisms action FXR treatment cholangitis (SC), we found that intestinally restricted activation effectively reduced...
Fibrosing cholangiopathies, including biliary atresia and primary sclerosing cholangitis, involve immune-mediated bile duct epithelial injury hepatic acid (BA) retention (cholestasis). Regulatory T-cells (Tregs) can prevent auto-reactive lymphocyte activation, yet the effects of BA on this CD4 subset are unknown. Gene regulatory networks for lymphocytes in a murine cholestasis model revealed Tregs polarized to Th17 during cholestasis. Following ligation, Stat3 deletion preserved Treg...